The Medical Briefing Nephrology
Diabetes and chronic kidney disease: 2026 KDIGO guidelines
Guidelines · KDIGO 2026 · draft
At a glance
■ Diabetes and CKD · KDIGO 2026 (draft)
SGLT2 inhibitors and GLP-1-based therapies first (1A), metformin as second line, finerenone as a strong recommendation in T2D: earlier cardio-renal triple therapy.
